MONTREAL -- (MARKET WIRE) -- March 08, 2007 -- TOPIGEN Pharmaceuticals Inc., an emerging biopharmaceutical company specializing in developing treatments for respiratory diseases, today announced it has commenced a second, expanded, 14-day Phase II clinical trial with one of its leading product candidates, inhaled TPI ASM8. TOPIGEN believes TPI ASM8 to be the first RNA-targeting drug with demonstrated efficacy in respiratory patients. This Phase II study is commencing as a result of initial positive Phase II results announced in July 2006 indicating that TPI ASM8 demonstrated protection in early and late stage allergic responses in patients with allergic asthma.
